Microbot Medical Inc. is excited to share the increasing global recognition of its innovative LIBERTY® Robotic Surgical System. The system is set to be presented at the Annual Congress of the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) on September 9, 2023. The presentation will be given by Professor Vincent Vidal, a Scientific Advisory Board Member of Microbot and an expert in Interventional Radiology.

The abstract and oral presentation, titled “Performance Evaluation of a Miniature and Disposable Endovascular Robotic Device,” was accepted after a successful pre-clinical trial conducted by a team of leading European interventional radiologists. The team expressed their positive experiences and satisfaction with the use of Microbot’s Robotic Surgery System.

Microbot believes that gathering peer-reviewed data during pre-clinical studies is crucial for gaining insights from physicians and future users. This data will help the company as it prepares for its First in Human (FIH) clinical trial and navigates the regulatory processes with the FDA in the USA and MDR in Europe.

The LIBERTY® Robotic Surgical System by Microbot Medical aims to revolutionize endovascular procedures. It eliminates the need for large, expensive equipment and reduces radiation exposure and physician strain. The remote operation feature of the LIBERTY® system has the potential to democratize endovascular interventional procedures.

Microbot Medical Inc. is a pre-clinical medical device company that specializes in transformative micro-robotic technologies. Its goal is to improve clinical outcomes for patients and enhance accessibility to medical procedures within the human body’s natural and artificial lumens.

For more information about Microbot Medical, visit their website at www.microbotmedical.com.

Source: Microbot Medical Inc.

Safe Harbor Statement: Forward-looking statements in this article are subject to various risks and uncertainties. These statements involve uncertainties, including market conditions, development and commercialization risks, regulatory approvals, and the need for future capital. Microbot Medical disclaims any intent or obligation to update these forward-looking statements.

Source: Microbot Medical Inc.